Supplementary Tables 1-3 from A First-in-Human Phase I Study of a Bivalent MET Antibody, Emibetuzumab (LY2875358), As Monotherapy and in Combination with Erlotinib in Advanced Cancer
openalex（2023）
Key words
Cancer Metabolism
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined